IBDEI0WU ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16278,1,3,0)
 ;;=3^796.3
 ;;^UTILITY(U,$J,358.3,16278,1,4,0)
 ;;=4^LOW BLOOD PRESSURE READING
 ;;^UTILITY(U,$J,358.3,16278,2)
 ;;=^273465
 ;;^UTILITY(U,$J,358.3,16279,0)
 ;;=796.2^^105^1014^9
 ;;^UTILITY(U,$J,358.3,16279,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16279,1,3,0)
 ;;=3^796.2
 ;;^UTILITY(U,$J,358.3,16279,1,4,0)
 ;;=4^ELEVATED B/P w/o HTN
 ;;^UTILITY(U,$J,358.3,16279,2)
 ;;=^273464
 ;;^UTILITY(U,$J,358.3,16280,0)
 ;;=285.9^^105^1015^1
 ;;^UTILITY(U,$J,358.3,16280,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16280,1,3,0)
 ;;=3^285.9
 ;;^UTILITY(U,$J,358.3,16280,1,4,0)
 ;;=4^ANEMIA
 ;;^UTILITY(U,$J,358.3,16280,2)
 ;;=^7007
 ;;^UTILITY(U,$J,358.3,16281,0)
 ;;=266.2^^105^1015^2
 ;;^UTILITY(U,$J,358.3,16281,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16281,1,3,0)
 ;;=3^266.2
 ;;^UTILITY(U,$J,358.3,16281,1,4,0)
 ;;=4^B12 & FOLATE ANEMIA
 ;;^UTILITY(U,$J,358.3,16281,2)
 ;;=^87347
 ;;^UTILITY(U,$J,358.3,16282,0)
 ;;=272.0^^105^1015^3
 ;;^UTILITY(U,$J,358.3,16282,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16282,1,3,0)
 ;;=3^272.0
 ;;^UTILITY(U,$J,358.3,16282,1,4,0)
 ;;=4^CHOLESTEROL (HYPER)
 ;;^UTILITY(U,$J,358.3,16282,2)
 ;;=^59973
 ;;^UTILITY(U,$J,358.3,16283,0)
 ;;=250.00^^105^1015^6
 ;;^UTILITY(U,$J,358.3,16283,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16283,1,3,0)
 ;;=3^250.00
 ;;^UTILITY(U,$J,358.3,16283,1,4,0)
 ;;=4^DIABETES MEL W/O COMP, TYPE II
 ;;^UTILITY(U,$J,358.3,16283,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,16284,0)
 ;;=250.02^^105^1015^5
 ;;^UTILITY(U,$J,358.3,16284,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16284,1,3,0)
 ;;=3^250.02
 ;;^UTILITY(U,$J,358.3,16284,1,4,0)
 ;;=4^DIAB MEL W/O COMP, TYPE II UNCONT
 ;;^UTILITY(U,$J,358.3,16284,2)
 ;;=^295704
 ;;^UTILITY(U,$J,358.3,16285,0)
 ;;=272.4^^105^1015^9
 ;;^UTILITY(U,$J,358.3,16285,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16285,1,3,0)
 ;;=3^272.4
 ;;^UTILITY(U,$J,358.3,16285,1,4,0)
 ;;=4^HYPERLIPIDEMIA
 ;;^UTILITY(U,$J,358.3,16285,2)
 ;;=^87281
 ;;^UTILITY(U,$J,358.3,16286,0)
 ;;=244.9^^105^1015^10
 ;;^UTILITY(U,$J,358.3,16286,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16286,1,3,0)
 ;;=3^244.9
 ;;^UTILITY(U,$J,358.3,16286,1,4,0)
 ;;=4^HYPOTHYROIDISM
 ;;^UTILITY(U,$J,358.3,16286,2)
 ;;=^123752
 ;;^UTILITY(U,$J,358.3,16287,0)
 ;;=250.01^^105^1015^4
 ;;^UTILITY(U,$J,358.3,16287,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16287,1,3,0)
 ;;=3^250.01
 ;;^UTILITY(U,$J,358.3,16287,1,4,0)
 ;;=4^DIAB MEL W/O COMP, TYPE I
 ;;^UTILITY(U,$J,358.3,16287,2)
 ;;=^33586
 ;;^UTILITY(U,$J,358.3,16288,0)
 ;;=278.01^^105^1015^11
 ;;^UTILITY(U,$J,358.3,16288,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16288,1,3,0)
 ;;=3^278.01
 ;;^UTILITY(U,$J,358.3,16288,1,4,0)
 ;;=4^OBESITY, MORBID
 ;;^UTILITY(U,$J,358.3,16288,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,16289,0)
 ;;=286.59^^105^1015^7
 ;;^UTILITY(U,$J,358.3,16289,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16289,1,3,0)
 ;;=3^286.59
 ;;^UTILITY(U,$J,358.3,16289,1,4,0)
 ;;=4^HEMOR D/O DUE TO CIRC ANTICOAG
 ;;^UTILITY(U,$J,358.3,16289,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,16290,0)
 ;;=268.9^^105^1015^12
 ;;^UTILITY(U,$J,358.3,16290,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16290,1,3,0)
 ;;=3^268.9
 ;;^UTILITY(U,$J,358.3,16290,1,4,0)
 ;;=4^VITAMIN D DEFICIENCY NOS
 ;;^UTILITY(U,$J,358.3,16290,2)
 ;;=^126968
 ;;^UTILITY(U,$J,358.3,16291,0)
 ;;=790.29^^105^1015^8
 ;;^UTILITY(U,$J,358.3,16291,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16291,1,3,0)
 ;;=3^790.29
 ;;^UTILITY(U,$J,358.3,16291,1,4,0)
 ;;=4^HYPERGLYCEMIA
 ;;^UTILITY(U,$J,358.3,16291,2)
 ;;=^329955
 ;;^UTILITY(U,$J,358.3,16292,0)
 ;;=389.9^^105^1016^7
